3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
4
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Carboplatin
88
pembrolizumab
85
Paclitaxel
71
Cyclophosphamide
63
Capecitabine
38
Doxorubicin
37
Taxes
29
130-nm albumin-bound paclitaxel
29
Cisplatin
25
Albumin-Bound Paclitaxel
22
Epirubicin
21
Drug Therapy
21
Docetaxel
20
sacituzumab govitecan
19
olaparib
19
camrelizumab
18
atezolizumab
18
Gemcitabine
17
eribulin
16
durvalumab
16
Bevacizumab
16
Radiotherapy
15
toripalimab
14
Specimen Handling
14
Biopsy
13
Everolimus
12
Magnetic Resonance Spectroscopy
11
apatinib
10
Nivolumab
10
talazoparib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Triple Negative Breast Neoplasms
×
zanidatamab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT05868226
2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1
Recruiting
124 enrolled